Meta-analysis of Response Rates Among Placebo-Treated Patients from Five Clinical Trials of Experimental Recurrent Clostridium difficile Therapeutics

D. Gerding¹, C. Jones², K. Blount², B. Shannon³

¹ Edward Hines Jr. VA Hospital, Hines, IL; ²Rebiotix Inc, Roseville, MN, ³Biorankings, LLC, St. Louis, MO

Background: The recognition of recurrent Clostridium difficile infections (rCDI) as an urgent health threat has led to development of therapeutics aimed at preventing or reducing recurrence, including RBX2660—a standardized microbiota-based drug manufactured from live human-derived microbes. In PUNCH CD2, a randomized, placebo-controlled Phase 2b trial of RBX2660 for rCDI, 20 of patients in the placebo arm met response criteria of no CDI recurrence within 8 weeks. To contextualize this result, we conducted a meta-analysis of response rates among placebo-treated patients in additional rCDI trials.

Methods: Five blinded, randomized, and placebo-controlled trials were included in this meta-analysis. Studies required patients to have ≥1 (1 study) or ≥2 prior CDI recurrences. All patients completed standard-of-care antibiotic course prior to experimental treatment. Four studies tested a vehicle placebo administered by the same route as the active treatment (oral, intravenous, or enema), and 1 study tested an autologous fecal transplant administered via enema. Response to treatment was defined as no CDI recurrence within 8-12 weeks. The proportional response rates with 95% confidence interval were calculated and compared in aggregate and among studies.

Results: A total of 154 of 292 placebo-treated patients (53%) met study-specific response criteria, with response rates ranging from 43%-58%. No study group presented a significantly different outcome from the aggregate cohort, and no correlation of response with placebo administration route was observed.

Conclusion: This meta-analysis demonstrates that response rates for blinded placebo-treated patients are consistent among 5 trials of experimental rCDI therapeutics, including a phase 2B trial of RBX2660. This analysis provides a useful framework for interpreting published rCDI trials, and for designing and interpreting future rCDI therapeutics trials.

This analysis was funded by Rebiotix Inc., Roseville, MN.

References <292 of 300 allowed characters>:

Dubberke et al., Abstract at ID Week 2016.
Figure 1. The Forest plot shows the placebo success rate for each study included in the meta-analysis with the addition of the aggregate result. Placebo group size is represented by circle diameter.